The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring

AIDS

Volumn 13, Issue 15, 1999, Pages 2083-2089

  Gatti, Giorgio ^a,d   Di Biagio, Antonio ^a   Casazza, Rosetta ^a   De Pascalis, Cleta ^a   Bassetti, Matteo ^a   Cruciani, Mario ^b   Vella, Stefano ^c   Bassetti, Dante ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Plasma concentrations; Ritonavir; Side effects; Therapeutic drug monitoring

Indexed keywords

RITONAVIR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 0032732512     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00011     Document Type: Article

References (23)

1. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
2. Danner SA, Carr A, Leonard JM, et al. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
3. Arribas JR, Lazzarin A, Martin T, Moroni M, Vanhove G, MacLeod C. Effect of dose escalation on the safety, tolerability and efficacy of ritonavir. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 8-12 November 1998 [Abstract P41].
4. Gatti G, Arribas JR, Lazzarin A, Martin T, Moroni M, Bassetti D. Ritonavir systemic exposure using a 14-day vs. a 7-day dose escalation scheme. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 8-12 November 1998 [Abstract P48].
5. Merry C, Barry M, Gibbons S, Mulcahy F, Back D. Improved tolerability of ritonavir derived from pharmacokinetic principles. Br J Clin Pharmacol 1996, 42:787.
6. Carpenter C, Fischl M, Hammer, et al. Updated recommendations of the International AIDS Society Panel - USA Panel. JAMA 1997, 277:1962-1969.
7. Gordon SM, Horsburgh CR, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993, 168:1559-1562.
8. Lake-Bakaar G, Winston T, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988, 109:471-473.
9. Macnab KA, Gill MJ, Sutherland LR, De Boer Visser N, Church D. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993, 31:421-428.
10. Gatti G, Guerra M, Miletich F, Gatti C, Cruciani M, Bassetti D. Comparative study of dapsone plasma levels in HIV+ patients and healthy volunteers using a population approach. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 15-18 September 1996.
11. Crivat M, Vittecoq D, Kodjo A, et al. Pharmacokinetic of saquinavir and study of intestinal function in HIV patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 28 September 28-1 October 1997 [Abstract A9].
12. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio JG. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother 1993, 37:1137-1143.
13. Gatti G, Papa P, Torre D, Andreoni M, et al. Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998, 42:2017-2023.
14. Casado JL, Perez-Elias MJ, Antela A, et al. Risk factors for ritonavir intolerance and outcome after change to indinavir [letter]. AIDS 1998, 12:335-336.
15. Norvir. Abbott Laboratories, Abbott Park, North Chicago, IL, USA. Prescribing information, June 1999.
16. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997, 41:898-905.
17. Taylor S, Dedicoat M, Hackforth S, et al. The use of ritonavir and saquinavir plasma level monitoring as an aid to dosage adjustment. 4th International Congress on Drug Therapy in HIV Infection. Glasgow, 8-12 November 1998 (Abstract P50].
18. Schapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
19. Gatti G, Di Biagio A, De Pascalis C, et al. High variability of indinavir parameters of systemic exposure in HIV+ patients observed prospectively in everyday clinical practice. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 24-27 September 1998 [Abstract A63].
20. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationship between exposure and antiviral effect. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 28 September-1 October 1997 [Abstract A15].
21. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
22. Dieleman J, Gyssens IC, Van Der Ende MEM, De Marie S, Burger DM. Urologic complaints in relation to indinavir plasma levels in HIV-infected patients. 12th World AIDS Conference. Geneva, 28 June-3 July 1998 [Abstract 12372].
23. Perello L, Goujard C, Delfraissy JF, Taburet AM. Therapeutic drug monitoring in HIV-infected patients receiving indinavir. 12th World AIDS Conference. Geneva, 28 June-3 July 1998